Efficacy of the Unified Protocol for transdiagnostic treatment of comorbid psychopathology accompanying emotional disorders compared to treatments targeting single disorders by Steele, Stephanie Jarvi et al.
Boston University
OpenBU http://open.bu.edu
Psychological and Brain Sciences BU Open Access Articles
2018-09-01
Efficacy of the Unified Protocol for
transdiagnostic treatment of
comorbid psychopathol...
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version Accepted manuscript
Citation (published version): Stephanie Jarvi Steele, Todd J Farchione, Clair Cassiello-Robbins,
Amanda Ametaj, Sophia Sbi, Shannon Sauer-Zavala, David H Barlow.
2018. "Efficacy of the Unified Protocol for transdiagnostic treatment
of comorbid psychopathology accompanying emotional disorders
compared to treatments targeting single disorders." JOURNAL OF








Efficacy of the Unified Protocol for Transdiagnostic Treatment of Comorbid Psychopathology 
Accompanying Emotional Disorders Compared to Treatments Targeting Single Disorders  
 
Stephanie Jarvi Steele, Ph.D., Todd J. Farchione, Ph.D., Clair Cassiello-Robbins, M.A., Amantia 
Ametaj, M.A., Sophia Sbi, B.S., Shannon Sauer-Zavala, Ph.D., & David H. Barlow, Ph.D. 
Boston University, Center for Anxiety and Related Disorders 
 
Boston University  
Center for Anxiety and Related Disorders 
648 Beacon Street, 6th Floor 
Boston, MA 02215 
 
Corresponding author: Stephanie Steele @ sjsteele@bu.edu 
Todd Farchione: tfarchio@bu.edu 
Clair Cassiello-Robbins: ccassiel@bu.edu 
Amantia Ametaj: amantiaa@bu.edu 
Sophia Sbi: ssbi@bu.edu 
Shannon Sauer-Zavala: ssauer@bu.edu 
David Barlow: dhbarlow@bu.edu  
 
TRANSDIAGNOSTIC TREATMENT FOR COMORBID PSYCHOPATHOLOGY 2 
Abstract 
Objective: This study aimed to examine whether the Unified Protocol (UP), a transdiagnostic 
cognitive-behavioral therapy for emotional disorders (i.e., anxiety, mood, and related disorders), 
is efficacious in the treatment of co-occurring emotional disorders compared to established single 
disorder protocols (SDPs) that target specific disorders (e.g., panic disorder). Method: 
Participants included 179 adults seeking outpatient psychotherapy. Participant age ranged from 
18 to 66 years, with an average of 30.66 years (SD = 10.77). The sample was 55% female and 
mostly Caucasian (83%). Diagnostic assessments were completed with the Anxiety Disorder 
Interview Schedule (ADIS), and disorder-specific, clinician-rated measures for the comorbid 
diagnoses of interest. Results: In both treatment conditions, participants’ mean number of 
diagnoses dropped significantly from baseline to posttreatment, and baseline to 12-month follow-
up. Additionally, large effects were observed for changes in comorbid generalized anxiety (ESSG: 
UP = -1.72; SDP = -1.98), social anxiety (ESSG: UP = -1.33, -0.86; SDP = -1.60, -1.54), and 
depression (ESSG: UP = -0.83; SDP = -0.84). Significant differences were not observed in 
between-group comparisons. Conclusions: Results suggest that both the UP and SDPs are 
efficacious in reducing symptoms of comorbid emotional disorders. The clinical, practical, and 
cost-effective advantages of transdiagnostic CBT are discussed.   
Keywords: Unified Protocol, cognitive-behavioral therapy, transdiagnostic treatment, 
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Efficacy of the Unified Protocol for Transdiagnostic Treatment of Comorbid Psychopathology 
Accompanying Emotional Disorders Compared to Treatments Targeting Single Disorders  
Emotional disorders (i.e., anxiety, mood, and related disorders; Barlow, 2000) are 
characterized by high rates of comorbidity (Barlow et al., 2016); for example, estimates of 
lifetime comorbidity rates for anxiety and depressive disorders are as high as 75% (Brown & 
Barlow, 2009). Research suggests that patients with comorbid emotional disorders demonstrate 
poorer treatment outcomes than patients with a single diagnosis (Rosellini et al., 2015). 
Specifically, comorbidity has been linked to chronicity and severity of psychopathology, relapse 
rates, treatment seeking, suicide potential, and overall psychosocial functioning (Brown et al., 
2001). 
Recent conceptualizations of the prevalent comorbidity amongst emotional disorders 
have emphasized the presence of shared underlying mechanisms that contribute to their onset 
(e.g., Wilamowska et al., 2010). Specifically, neuroticism, defined as the tendency for frequent 
and intense negative emotions accompanied by perceived lack of control over these experiences, 
has been implicated across a range of conditions (Barlow et al., 2014), and higher levels of this 
trait are associated with increased rates of comorbidity (Griffith et al., 2010). Beyond the 
neurotic temperament, individuals with emotional disorders also display shared functional 
processes that maintain their symptoms; specifically, frequently occurring negative emotions are 
perceived as aversive, prompting avoidant coping that ultimately increases the frequency and 
intensity of these experiences (see Sauer-Zavala & Barlow, 2014).  
Transdiagnostic interventions that target shared mechanisms may confer both clinical and 
practical advantages over more traditional protocols focused on a single Diagnostic and 
Statistical Manual (DSM; e.g., American Psychiatric Association, 2013) disorder (Sauer-Zavala 
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et al., 2017). First, by directly targeting common processes, transdiagnostic treatments can 
simultaneously address symptoms of co-occurring conditions. Additionally, transdiagnostic 
approaches may address the time and training burden that has limited successful dissemination of 
evidence-based psychological treatments as clinicians need only learn the basics of one treatment 
approach to provide research supported care to a range of common presentations. Several studies 
have found transdiagnostic treatments to be efficacious in the treatment of emotional conditions 
(Akbari et al., 2015; Milosevic et al., 2017; Palermo et al., 2016), as well as in the treatment of 
comorbid emotional disorders compared to other specific interventions or treatment as usual 
more broadly (Stice et al., 2015; Titcov, et al., 2015).  
The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP; Barlow 
et al., 2011a; Barlow et al., 2011b; Barlow et al., 2018a; Barlow et al., 2018b) is a 
transdiagnostic, cognitive-behavioral intervention consisting of 5 core modules that target the 
abovementioned temperamental characteristics underlying all anxiety, depressive, and related 
disorders. The UP has demonstrated efficacy in reducing general symptoms of anxiety and 
depression (Ellard et al., 2010; Farchione et al., 2012) and these improvements were maintained 
18 months after treatment (Bullis et al., 2014). Further, in a recently conducted larger clinical 
trial comparing the UP to gold-standard, single-disorder protocols (SDPs) for generalized anxiety 
disorder (GAD), social anxiety disorder (SAD), Panic Disorder (PD), and obsessive-compulsive 
disorder (OCD), the transdiagnostic UP approach led to equivalent symptom reduction on 
patients’ principal diagnosis compared to the SDP associated with that disorder. Notably, the UP 
condition evidenced lower rates of attrition than the SDP condition (Barlow et al., 2017). 
The current study aimed to explore the efficacy of the UP in treating comorbid emotional 
conditions in a diagnostically heterogeneous sample from this larger clinical trial (Barlow et al., 
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2017). Specially, this study had three aims: 1) Characterize comorbidity in the current sample, 2) 
Evaluate whether the UP indeed leads to reductions in symptoms of comorbid disorders, and 3) 
Compare the UP to established SDPs in the reduction of comorbid psychopathology.  
Methods 
Participants 
Individuals in the present study were a subset of participants from a clinical trial 
comparing two active treatment conditions (UP and SDPS targeting four principal anxiety 
disorders) and a waitlist control condition (n = 223; see Barlow et al., 2017). The current study 
included those participants who received psychological treatment during the trial (n = 179), and 
excluded individuals that were randomized to the waitlist condition. Additional information 
regarding inclusion and exclusion criteria can be found in Barlow et al. (2017).  
Participants in the current subsample ranged in age from 18 to 66 years old, with an 
average age of 30.60 years (SD = 10.70). The majority of the sample identified as female 
(55.30%), non-Hispanic White (76.0%), and college educated or higher (65.40%). All 
participants met diagnostic criteria for at least one principal (most interfering and severe) anxiety 
disorder restricted to the following four categories: panic disorder, with or without agoraphobia 
(PD/A; n = 47 [26.30%]); generalized anxiety disorder (GAD; n = 49 [27.40%]), obsessive-
compulsive disorder (OCD; n = 35 [19.60%]), or social anxiety disorder (SAD; n = 48 
[26.80%]). Clinical diagnoses were made with the Anxiety Disorder Interview Schedule (ADIS; 
Di Nardo et al., 1994; Brown & Barlow, 2014). 
Procedures 
The clinical trial was approved by the study site’s Institutional Review Board, and all 
participants provided written informed consent prior to enrolling. The current study was carried 
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out in accordance with the latest version of the Declaration of Helsinki. As noted above, 
participants were randomized to either a waitlist condition or treatment with the UP or SDPs 
corresponding to their principal diagnosis (1:2:2 allocation ratio, respectively). All participants 
were assigned one principal diagnosis after administration of a diagnostic interview (see 
Measures below); if randomized to the SDP condition, the principal diagnosis determined which 
SDP the participant received. SDPs included: 1) SAD: Managing Social Anxiety: A Cognitive-
Behavioral Therapy Approach – 2nd edition (MSA-II; Hope et al., 2006; Hope et al., 2000); 2) 
PD/A: Mastery of Your Anxiety and Panic – 4th edition (MAP-IV; Barlow & Craske, 2007; 
Craske & Barlow, 2007); 3) GAD: Mastery of Your Anxiety and Worry – 2nd edition (MAW-II; 
Craske & Barlow, 2006; Zinbarg et al., 2006); and 4) OCD: Treating Your OCD with Exposure 
and Response (Ritual) Prevention Therapy – 2nd edition (Foa et al., 2012; Yadin et al., 2012).  
The number and duration of sessions was determined via published guidelines associated 
with each SDP protocol; UP treatment (session number/duration) was provided in accordance 
with recommendations for the SDP corresponding to the patient’s principal diagnosis. 
Specifically, patients with GAD, SAD, and OCD received 16 sessions (within a 21-week 
treatment window) and patients with PD/A received 12 sessions (within a 16-week treatment 
window). Further, sessions were 50-minutes in duration, with the exception of treatment for 
participants with a principal diagnosis of OCD, for whom sessions lasted 90 minutes. To ensure 
treatment fidelity, expert raters associated with the development of each protocol assessed 20% 
of randomly selected treatment sessions for adherence and competence. Overall scores for 
treatment fidelity fell in the good to excellent range (M: UP = 4.44/5; SDPs = 4.09/5).  
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Patients were also required to attend assessment visits while enrolled in the trial. Data 
were collected at baseline, posttreatment, and 12-month follow-up. All assessments were 
conducted by independent study evaluators who were blinded to participants’ study condition. 
Measures  
Anxiety Disorders Interview Schedule (ADIS; Di Nardo, et al., 1994; Brown & 
Barlow, 2014). The ADIS is a semi-structured clinical interview based on diagnostic criteria 
from the Diagnostic and Statistical Manual (DSM; APA, 2013). Study evaluators assessed 
patients using the ADIS for anxiety, mood, somatic symptom disorders, and substance use 
disorders, and screened them for other disorders (e.g., ADHD, eating disorders). Due to the 
publication of DSM-5 (APA, 2013) partway through the clinical trial, 137 patients (76.5%) were 
assigned diagnoses based on DSM-IV criteria and 42 patients (23.5%) were assigned diagnoses 
based on DSM-5 criteria. Since panic disorder and agoraphobia are separated in DSM-5, study 
evaluators rated these diagnoses together as overall PD/A symptoms for those patients diagnosed 
according to the new diagnostic criteria in DSM-5 (APA, 2013). 
Panic Disorder Severity Scale (PDSS; Shear et al., 1997). The PDSS is a brief, 7-item, 
clinician-rated measure that was designed to assess panic disorder symptoms and their impact on 
an individual’s functioning. Each item on the PDSS falls on a 5-point Likert-scale, with higher 
scores indicating higher symptom severity and impairment. The PDSS displays good concurrent 
validity and inter-rater reliability, including in treatment outcome research for patients with panic 
disorder with or without agoraphobia (Shear et al., 1997; Shear et al., 2001a; Wuyek et al., 
2011). Study evaluators administered the PDSS to all participants with a clinical PD/A diagnosis 
at all assessment visits. 
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Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987). The LSAS is a 24-item, 
clinician-rated scale that measures both fear and avoidance of social interactions and 
performances. A total score was obtained by adding the separate fear and avoidance scores for 
each item, with higher scores indicating higher severity. The LSAS has demonstrated strong 
internal consistency and convergent validity with other measures of SAD (Fresco et al., 2001; 
Heimberg, et al., 1999). Study evaluators administered the LSAS to all patients in the trial with a 
clinical SAD diagnosis at all assessment time-points. 
Generalized Anxiety Disorder Severity Scale (GADSS; Shear et al., 2006). The 
GADSS is a 6-item, clinician-rated measure that evaluates core symptoms of GAD and their 
impact on an individual’s functioning. Items are rated on a 5-point scale, ranging from 0 (none) 
to 4 (very severe). Psychometric studies have shown that the GADSS has high internal 
consistency, good convergent validity with other measures, and captures changes in symptoms 
and impairment over the course of treatment (Shear et al., 2006). Study evaluators administered 
the GADSS to all patients in the trial with a clinical GAD diagnosis at all assessments. 
Yale-Brown Obsessive Compulsive Scale Interview-2nd edition (Y-BOCS-II; 
Goodman et al., 1989; Storch et al., 2010). The Y-BOCS-II is a 10-item, clinician-rated 
interview designed to assess severity of OCD symptoms and resulting impairment. Items on the 
scale are scored on a 0 (none) to 5 (extreme) Likert-scale. The Y-BOCS has demonstrated high 
internal consistency, one-week test–retest reliability, and interrater reliability as well as good 
construct validity (Goodman et al., 1989; Storch et al., 2010; Wu et al., 2016). Patients with an 
OCD diagnosis were given a 64-item checklist at baseline, listing possible obsessions and 
compulsions. In addition, these patients were administered the Y-BOCS-II at all assessment 
visits. 
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Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D; 
Williams, 1988). The SIGH-D is a 17-item, clinician-rated interview guide that was developed to 
provide specific instructions for administration and scoring of the Hamilton Rating Scale for 
Depression (HRSD; Hamilton, 1960; Shear et al., 2001b). The SIGH-D has demonstrated good 
inter-rater and test-retest reliability (Shear et al., 1988). This interview was completed with all 
participants at each assessment point. 
Results 
Aim 1. A summary of the diagnostic composition of the sample can be viewed in Table 
1. Comorbidity was highly prevalent; 150 (83.80%) participants met diagnostic criteria for at 
least one co-occurring disorder at baseline assessment, with a range of one to seven diagnoses (M 
= 2.49, SD = 1.44). Chi square analyses indicated no significant differences in the presence of 
comorbid diagnoses as a function of treatment condition at baseline, χ2 (1, n = 179) = .25, p = 
.61, phi = .05. Notably, almost half of the GAD sample met diagnostic criteria for co-occurring 
SAD. Co-occurring PD and GAD were diagnosed most frequently among participants with 
principal OCD. 
Aim 2. The second aim of this study was to explore the extent to which the UP addresses 
comorbid disorders in a diagnostically heterogeneous sample with a high degree of co-occurring 
conditions. To address this aim, we first examined the UP’s efficacy in significantly reducing 1) 
the number of clinically significant diagnoses on the ADIS from baseline to posttreatment and 
baseline to 12-month follow-up and 2) scores on disorder-specific, clinician-rated measures from 
baseline to posttreatment and baseline to 12-month follow-up. First, paired-samples t-tests were 
conducted to evaluate the impact of the UP on participants’ mean number of clinically significant 
diagnoses. There was a statistically significant decrease in number of diagnoses from baseline (M 
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= 2.56, SD = 1.47) to posttreatment (M = .84, SD = 1.30), t (62) = 8.96, p < .0005, and baseline 
(M = 2.42, SD = 1.40) to 12-month follow-up (M = .83, SD = 1.20), t (68) = 9.41, p < .0005.  
Next, to ensure that our estimates were limited to the UP’s effects on comorbid 
conditions, we restricted our sample to include individuals with co-occurring PD/A (or PD or 
AG), SAD, GAD, OCD, major depressive disorder (MDD), and persistent depressive disorder 
(PDD), which were evaluated at each time point by clinician-rated, disorder-specific measures 
(see Method). For example, individuals with a principal diagnosis of SAD were removed from 
our evaluations of change on the LSAS, our measure of SAD severity. Standardized Mean Gain 
Effect sizes (ESSG) were calculated to determine the magnitude of change from baseline to 
posttreatment, and baseline to 12-month follow-up. Standardized mean gain was chosen for these 
analyses due its inclusion of a correction for repeated measures assessments (King et al., 2006). 
Large effects were seen for change on the GADSS, LSAS, and HAM-D (see Table 2). Due to 
small number of individuals with comorbid PD/A and OCD, analyses were not completed for the 
PDSS baseline to posttreatment (n = 2), or the YBOCS for posttreatment (n = 2) or 12-month 
follow-up (n = 2). 
 Aim 3. As described above, Aim 3 of the present study was to explore whether the 
transdiagnostic UP approach was associated with greater decreases in comorbid conditions than 
single disorder approaches designed to address one primary condition. Consistent with analytic 
procedures used in our primary outcomes paper (Barlow et al., 2017), we combined the 
individual SDPs into one variable to represent all of the SDPs used in the trial. Similar to Aim 2, 
we compared the UP to SDP on 1) number of clinically significant diagnoses on the ADIS at 
baseline, posttreatment, and 12-month follow-up, and 2) scores on disorder-specific measures 
from baseline to post-treatment, and baseline to 12-month follow-up. First, independent samples 
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t-tests revealed no significant differences for mean number of diagnoses between the UP and 
SDPs at baseline (UP M = 2.48, SD = 1.44; SDP M = 2.51, SD = 1.46; t (177) = -.13, p = .90), 
posttreatment (UP M = .84, SD = 1.30; SDP M = 1.05, SD = 1.27; t (118) = -.90, p = .37), or 12- 
month follow-up (UP M = .82, SD = 1.20; SDP M = .83, SD = 1.21; t (132) = -.02, p = .98). 
To evaluate changes on the disorder-specific measures by treatment condition at each 
time point, within group and between group effect sizes were examined. Again, individuals with 
the principal diagnosis associated with each disorder-specific measure were removed, allowing 
for examination of specific change in comorbid diagnoses. And again, due to small sample sizes, 
analyses were not completed for the PDSS or the YBOCS. Effect sizes (ESSG) were calculated to 
determine the magnitude of change from pre- to post-treatment and from pre-treatment to follow-
up for the SDP condition (see Table 2). Similar to the UP condition, large effects were seen for 
change on the GADSS, LSAS, and HAM-D. Next, between group effect sizes (Hedge’s g, with 
correction for small sample size) were calculated to determine the magnitude of the difference 
between conditions at each time point on disorder-specific symptom measures (see Table 3). 
Very small, nonsignificant effects were observed on the HAM-D (-0.04 to 0.10) at all time points 
between the UP and SDP, and small to moderate (though still nonsignificant) effects were 
observed on the GADSS (-0.4 to 0.6) and LSAS (-0.5 to 0.6). In sum, results suggested that there 
were no significant differences between UP and SDP in decreasing comorbid symptoms at 
posttreatment and 12-month follow-up for GAD, SAD, or DEP. 
Discussion 
The ability to elegantly address symptoms of comorbid conditions is often cited as a 
potential advantage of transdiagnostic interventions. The primary purpose of the present study 
was to explore whether a leading transdiagnostic treatment, the UP, leads to improvements in co-
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occurring disorders. Indeed, results suggest that the UP is efficacious in reducing symptoms of 
comorbid psychopathology; specifically, participants in the UP condition evidenced significant 
decreases in mean number of clinically significant diagnoses from baseline to posttreatment, and 
baseline to 12-month follow-up. Similarly, significant changes on clinician-rated, disorder-
specific measures were also observed at each time point. A secondary aim of the present study 
was to compare this change in comorbid disorder symptoms following treatment with the UP to 
treatment with leading and well established SDPs. Contrary to expectations, significant 
differences were not found when comparing the UP and SDP in the reduction of comorbid 
psychopathology; that is, both treatments led to decreases in mean number of diagnoses, and 
decline in symptoms of co-occurring conditions on disorder-specific measures. 
Few studies have investigated the effect of treatment on comorbid disorders. However, in 
several studies, treatment for a principal anxiety disorder resulted in significant declines in the 
frequency of comorbid disorders from pretreatment to posttreatment (e.g., Allen et al., 2007; 
Craske et al., 2007). Davis et al. (2010) reported similar findings in a naturalistic sample taken 
from our clinical center; specifically, treatment for principal anxiety and depressive disorders led 
to decreases in the number of patients with comorbid disorders.  
Consistent with these findings, the lack of significant differences observed by treatment 
condition in this study suggests that both the UP and SDPs are efficacious treatments for co-
occurring emotional disorders. The lingering question is, why? One potential explanation for 
these findings lies in the similarities of the treatments; skills presented in both the UP and SDPs 
were similar and often overlapped (e.g., cognitive interventions, exposures), although these 
skills, and other aspects of treatment, are very specifically targeted in SDPs and require 
somewhat different application procedures. Nevertheless, the fact that participants were able to 
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generalize these skills is quite encouraging from a clinical standpoint, and speaks to the broad-
based and transdiagnostic utility of cognitive-behavioral treatment elements. Another possibility, 
consistent with a more mechanism-based perspective of psychopathology, is that both treatments 
resulted in changes to underlying, core processes common to the range of emotional disorders, 
such as neuroticism. Although SDPs did not directly target shared mechanisms, at least in the 
way that the UP was designed to do, many of the procedures were similar and it is possible that 
changes occurred at that level. Further investigation in this area is needed.   
Current findings support the practical and cost-effective nature of incorporating 
transdiagnostic treatments into both clinical training programs and routine clinical practice. As 
outpatient psychotherapy continues to shift away from the standard 50-minute session (Olfson & 
Marcus, 2010), dissemination of effective science-based treatment is becoming even more 
critical in our field. Training clinicians to use one set of research supported modules for patients 
presenting with heterogeneous, co-occurring psychological disorders reduces the time and effort 
it takes to learn multiple SDPs, the cost of training, supervising, and implementing different 
manualized treatments for different diagnoses, and provides the potential for more efficient and 
more broad-based dissemination of effective treatment (McHugh & Barlow, 2010). Thus, 
transdiagnostic treatments offer a promising avenue for treating co-occurring emotional disorders 
to address the comorbid, complex presentations regularly seen in routine clinical practice. 
 Despite promising early findings, study limitations warrant mention. As published 
previously, participants reported generally high levels of education and lower depression than 
comparable participant samples. Additionally, the UP and three of the four SDPs included were 
developed at the data collection/treatment site, potentially limiting generalizability (Barlow et al., 
2017). Specific to the current study’s focus on comorbid conditions, sample sizes were small 
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after removing principal diagnoses, limiting between-group comparisons across time points in 
some instances. Specifically, sample sizes were small for comparisons on diagnosis-specific 
measures after principal diagnoses were removed. A power analysis in G*Power (Faul, 
Erdfelder, Lang, & Buchnear, 2007) indicated that a minimum of 52 patients (26 per group) 
would be necessary to explore changes on diagnosis-specific measures (e.g., using t-tests) to be 
adequately powered to find a large effect. Of note, the current study was adequately powered for 
the between-group analyses examining changes in number of diagnoses between conditions. 
 In sum, both treatments were effective in reducing comorbid symptoms. This study offers 
preliminary evidence for the UP’s efficacy in treating co-occurring emotional disorders. Current 
results require further study through replication and in different clinical settings. Future work is 
needed to more specifically understand how these outcomes are achieved (i.e., which underlying 
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